X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (100) 100
oncology (78) 78
index medicus (66) 66
female (57) 57
male (57) 57
middle aged (53) 53
aged (46) 46
adult (43) 43
cancer (35) 35
lung neoplasms - drug therapy (32) 32
chemotherapy (28) 28
carcinoma, non-small-cell lung - drug therapy (27) 27
lung cancer (27) 27
lung neoplasms - pathology (25) 25
gefitinib (24) 24
antineoplastic combined chemotherapy protocols - therapeutic use (23) 23
lung neoplasms - genetics (23) 23
treatment outcome (23) 23
respiratory system (22) 22
carcinoma, non-small-cell lung - genetics (19) 19
therapy (18) 18
cell lung-cancer (17) 17
open-label (17) 17
antineoplastic agents - therapeutic use (16) 16
mutation (16) 16
prognosis (16) 16
protein kinase inhibitors - therapeutic use (16) 16
carcinoma, non-small-cell lung - pathology (15) 15
disease-free survival (15) 15
survival rate (15) 15
cisplatin - administration & dosage (14) 14
neoplasm staging (14) 14
aged, 80 and over (13) 13
lung cancer, non-small cell (13) 13
research (13) 13
adenocarcinoma (12) 12
apoptosis (12) 12
care and treatment (12) 12
prospective studies (12) 12
receptor, epidermal growth factor - genetics (12) 12
adenocarcinoma - genetics (11) 11
expression (10) 10
survival (10) 10
adenocarcinoma - pathology (9) 9
carcinoma, hepatocellular - drug therapy (9) 9
egfr mutations (9) 9
erlotinib (9) 9
liver neoplasms - drug therapy (9) 9
quinazolines - therapeutic use (9) 9
survival analysis (9) 9
trial (9) 9
tumors (9) 9
acquired-resistance (8) 8
analysis (8) 8
antineoplastic agents - administration & dosage (8) 8
carcinoma, hepatocellular - mortality (8) 8
combination (8) 8
health aspects (8) 8
hepatocellular carcinoma (8) 8
lung neoplasms - mortality (8) 8
multicenter (8) 8
proportional hazards models (8) 8
tyrosine kinase inhibitors (8) 8
1st-line treatment (7) 7
abridged index medicus (7) 7
adenocarcinoma - drug therapy (7) 7
animals (7) 7
carcinoma, hepatocellular - blood (7) 7
carcinoma, hepatocellular - pathology (7) 7
cell biology (7) 7
cell line, tumor (7) 7
clinical trials (7) 7
drug administration schedule (7) 7
hematology, oncology and palliative medicine (7) 7
hepatoma (7) 7
liver neoplasms - mortality (7) 7
liver neoplasms - pathology (7) 7
pharmacology & pharmacy (7) 7
phase-iii trial (7) 7
randomized-trial (7) 7
receptor, epidermal growth factor - antagonists & inhibitors (7) 7
smoking (7) 7
activation (6) 6
antineoplastic agents - adverse effects (6) 6
carboplatin - administration & dosage (6) 6
cirrhosis (6) 6
drug therapy (6) 6
genetic aspects (6) 6
infection (6) 6
liver cancer (6) 6
liver neoplasms - blood (6) 6
lung neoplasms - metabolism (6) 6
medicine & public health (6) 6
molecular targeted therapy (6) 6
mutations (6) 6
nasopharyngeal carcinoma (6) 6
quality of life (6) 6
risk factors (6) 6
surgery (6) 6
time factors (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Respiration, ISSN 0025-7931, 2018, Volume 96, Issue 4, pp. 303 - 304
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2011, Volume 29, Issue 21, pp. 2866 - 2874
Purpose The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/paclitaxel in previously untreated never-smokers and light... 
TRIAL | CHEMOTHERAPY-NAIVE PATIENTS | FACTOR-RECEPTOR GENE | PLACEBO | ONCOLOGY-GROUP | ONCOLOGY | TYROSINE KINASE | SENSITIVITY | EGFR MUTATIONS | MOLECULAR PREDICTORS | PREVIOUSLY TREATED PATIENTS | Immunohistochemistry | Lung Neoplasms - drug therapy | Predictive Value of Tests | Adenocarcinoma - pathology | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Time Factors | Gefitinib | Odds Ratio | Paclitaxel - administration & dosage | Adenocarcinoma - chemistry | Precision Medicine | ErbB Receptors - antagonists & inhibitors | Lung Neoplasms - chemistry | Risk Assessment | Risk Factors | Carboplatin - administration & dosage | In Situ Hybridization, Fluorescence | Logistic Models | Survival Rate | Adenocarcinoma - drug therapy | Biomarkers, Tumor - genetics | Mutation | Carcinoma, Non-Small-Cell Lung - chemistry | Adenocarcinoma of Lung | ErbB Receptors - genetics | Lung Neoplasms - pathology | Patient Selection | Female | Adenocarcinoma - genetics | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Biomarkers, Tumor - analysis | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Gene Dosage | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | ErbB Receptors - analysis | Adenocarcinoma - mortality
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2009, Volume 15, Issue 6, p. 2076
Purpose: We aim to develop a digital PCR-based method for the quantitative detection of the two common epidermal growth factor receptor ( EGFR ) mutations... 
lung cancer | mutation | digital PCR | plasma DNA | EGFR
Journal Article
Cancer, ISSN 0008-543X, 09/2015, Volume 121, Issue S17, pp. 3130 - 3145
Journal Article
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 2014, Volume 11, Issue 7, pp. 381 - 382
Over the past three decades, the interpretation of clinical trial outcomes in studies of advanced-stage non-smallcell lung cancer has changed. The robustness... 
CELL LUNG-CANCER | ONCOLOGY | GEFITINIB | Chemotherapy | Patient outcomes | Genetic aspects | Research | Lung cancer, Non-small cell | Drug therapy | Health aspects | Cancer
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 11/2011, Volume 8, Issue 11, pp. 661 - 668
Lung cancer is a complex and often fatal disease. The recent discovery of activating mutations in EGFR and fusion genes involving ALK has set the stage for... 
GENE-MUTATIONS | KRAS MUTATIONS | SUPPORTIVE CARE | PHASE-II TRIAL | GEFITINIB | ONCOLOGY | FACTOR RECEPTOR MUTATIONS | ACQUIRED-RESISTANCE | RANDOMIZED-TRIAL | EGFR MUTATIONS | PREVIOUSLY TREATED PATIENTS | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Clinical Trials as Topic - statistics & numerical data | Humans | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Neoplasm Proteins - antagonists & inhibitors | Molecular Targeted Therapy | Biomarkers, Tumor | Endpoint Determination | Neoplasm Proteins - genetics | Precision Medicine | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Combined Modality Therapy | Lung Neoplasms - therapy | Protein Kinase Inhibitors - administration & dosage | Carcinoma, Non-Small-Cell Lung - therapy | Genes, erbB-1 | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Oncogene Proteins, Fusion - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - drug therapy | Clinical Trials as Topic - methods | Research Design | Usage | Pharmacogenetics | Respiratory agents | Genetic aspects | Research | Lung cancer, Non-small cell | Drug therapy | Health aspects | Risk factors
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2016, Volume 34, Issue 1, pp. 91 - 101
Ethnic and geographic differences in cancer incidence, prognosis, and treatment outcomes can be attributed to diversity in the inherited (germline) and somatic... 
CELL LUNG-CANCER | KRAS MUTATIONS | BREAST-CANCER | WIDE ASSOCIATION ANALYSIS | ONCOLOGY | FACTOR RECEPTOR MUTATIONS | PROSTATE-CANCER | TYROSINE KINASE INHIBITOR | CLINICAL CHARACTERISTICS | EGFR MUTATIONS | ACTIVATING MUTATIONS | Geography | Ethnic Groups | Prognosis | Neoplasms - genetics | Healthcare Disparities - standards | Genomics | Humans | Index Medicus
Journal Article
Asia-Pacific Journal of Clinical Oncology, ISSN 1743-7555, 09/2008, Volume 4, Issue 3, pp. 123 - 124
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2016, Volume 34, Issue 24, pp. 2858 - 2865
Journal Article